As of 06 Nov 2026 05:17 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2025/054 (15 Oct 2025): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Exenatide (Bydureon® BCise®) 2mg/0.85ml prolonged-release suspension for injection pre-filled pensaffected product · inferred from phrasing | Discontinued, as stated | — not stated for this line | notice of 15 Oct 2025 |
| Alternative GLP-1 RAs and dual GIP/GLP-1 RAclass-level statement by the source, not a named product · inferred from phrasing | Stated as available | — not stated for this line | notice of 15 Oct 2025 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
The latest recorded notice names no alternative as remaining available.
Identifiers — Exenatide
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Sep 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
One supply notification on record, 15 Oct 2025. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 15 Oct 2025 | Medicine Supply Notification: Exenatide (Bydureon® BCise® ) 2mg/0.85ml prolonged-release suspension for injection pre-filled pen | Supply notification | Tier 2 | MSN/2025/054 |
Also recorded under
Bracketed names seen in this medicine's notice titles: bydureon bcise. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2025)48 Exenatide (Bydureon® BCise®) 2mg/0.85ml prolonged-release suspension for · issued 27 Oct 2025 · valid until noted product have been discontinued, as stated · matched by name PDF ↗